Volume 1402, Issue 3 (10-2023)
2023, 1402(3): 0-0 |
Back to browse issues page
Ethics code: IR.MEDILAM.REC.1400.131
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
khoshnood S, Sadeghifard N, hydari M, Hassankaviar V, karamolahi S, hashemian M et al . Evaluation of the global prevalence of clarithromycin resistance in Helicobacter pylori: A systematic review and meta-analysis. Journal title 2023; 1402 (3)
URL: http://newresearch.medilam.ac.ir/article-1-1508-en.html
URL: http://newresearch.medilam.ac.ir/article-1-1508-en.html
Saeed Khoshnood , Nourkhoda Sadeghifard , Mohsen Hydari , Vahab Hassankaviar , Somaye Karamolahi , Marzieh Hashemian , Hedayat Heidarizadeh
Clinical Microbiology Research Center
Abstract: (593 Views)
International guidelines for Helicobacter pylori recommend that the regional prevalence of Helicobacter pylori antibiotic resistance be used to select the right antibiotic and treatment regimen. In fact, knowing the level of antibiotic resistance plays an important role in choosing the appropriate treatment and reducing the rate of treatment failures. When the prevalence of clarithromycin resistance in an area is more than 20%, guidelines recommend that allergy testing for Helicobacter pylori be performed before treatment with this antibiotic.As clarithromycin is the standard treatment for Helicobacter pylori and is prescribed experimentally in most countries, several studies have shown that resistance to this antibiotic is increasing to more than 20% in most areas. Has been reported. Therefore, the aim of this study is to systematically evaluate the resistance of clarithromycin worldwide. The results of this study can inform physicians and specialists to prescribe the correct treatment regimen to increase the eradication of Helicobacter pylori and reduce the failure rate of treatment And recurrence of infections help.In fact, in areas where resistance to this antibiotic is reported to be more than 20%, allergy testing for this antibiotic should be performed before starting treatment and experimental treatment with this antibiotic should be avoided.
Received: 2021/06/7 | Accepted: 2021/07/24 | Published: 2023/10/2
Send email to the proposal executer
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |